药明生物(02269.HK)推全新微生物表达平台EffiX

阿斯达克财经
04 Mar

药明生物(02269.HK) 宣布推出创新技术平台EffiX,该平台基于大肠杆菌表达系统建立,旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA,通过提供全面且具有成本效益的CMC策略,简化工艺开发流程,可以满足从研究到商业化生产的各种项目服务需求,协助全球合作伙伴加速研发创新生物疗法。

药明生物首席执行官陈智胜表示,推出创新技术平台EffiX及升级微生物解决方案,是为了更好地赋能全球合作伙伴,无论产品处于任何开发阶段,该平台都能够在保证产品质量的前提下,提供出色的产量、可扩展性及灵活性。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10